Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Protein kinase N3 deficiency impedes PI3-kinase pathway-driven leukemogenesis without affecting normal hematopoiesis.

Literature DB >> 25234167

Protein kinase N3 deficiency impedes PI3-kinase pathway-driven leukemogenesis without affecting normal hematopoiesis.

M Kraus¹, B Dolinski¹, T W Rosahl², J A Magee³.

Abstract

Entities: Gene

Mesh：

Substances：

Year: 2014 PMID： 25234167 DOI： 10.1038/leu.2014.278

Source DB: PubMed Journal: Leukemia ISSN： 0887-6924 Impact factor: 11.528

× No keyword cloud information.

14 in total

Review 1. The multiple roles of PTEN in tumor suppression.

Authors: A Di Cristofano; P P Pandolfi
Journal: Cell Date: 2000-02-18 Impact factor: 41.582

2. The interaction of PKN3 with RhoC promotes malignant growth.

Authors: Keziban Unsal-Kacmaz; Shoba Ragunathan; Edward Rosfjord; Stephen Dann; Erik Upeslacis; Mary Grillo; Richard Hernandez; Fiona Mack; Anke Klippel
Journal: Mol Oncol Date: 2011-12-28 Impact factor: 6.603

3. Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at histone H3K4.

Authors: Eric Metzger; Axel Imhof; Dharmeshkumar Patel; Philip Kahl; Katrin Hoffmeyer; Nicolaus Friedrichs; Judith M Müller; Holger Greschik; Jutta Kirfel; Sujuan Ji; Natalia Kunowska; Christian Beisenherz-Huss; Thomas Günther; Reinhard Buettner; Roland Schüle
Journal: Nature Date: 2010-03-14 Impact factor: 49.962

4. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia.

Authors: Teresa Palomero; Maria Luisa Sulis; Maria Cortina; Pedro J Real; Kelly Barnes; Maria Ciofani; Esther Caparros; Jean Buteau; Kristy Brown; Sherrie L Perkins; Govind Bhagat; Archana M Agarwal; Giuseppe Basso; Mireia Castillo; Satoru Nagase; Carlos Cordon-Cardo; Ramon Parsons; Juan Carlos Zúñiga-Pflücker; Maria Dominguez; Adolfo A Ferrando
Journal: Nat Med Date: 2007-09-16 Impact factor: 53.440

5. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor.

Authors: Matthew R Janes; Jose J Limon; Lomon So; Jing Chen; Raymond J Lim; Melissa A Chavez; Collin Vu; Michael B Lilly; Sharmila Mallya; S Tiong Ong; Marina Konopleva; Michael B Martin; Pingda Ren; Yi Liu; Christian Rommel; David A Fruman
Journal: Nat Med Date: 2010-01-13 Impact factor: 53.440

6. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia.

Authors: Alejandro Gutierrez; Takaomi Sanda; Ruta Grebliunaite; Arkaitz Carracedo; Leonardo Salmena; Yebin Ahn; Suzanne Dahlberg; Donna Neuberg; Lisa A Moreau; Stuart S Winter; Richard Larson; Jianhua Zhang; Alexei Protopopov; Lynda Chin; Pier Paolo Pandolfi; Lewis B Silverman; Stephen P Hunger; Stephen E Sallan; A Thomas Look
Journal: Blood Date: 2009-05-20 Impact factor: 22.113

7. PKN3 is required for malignant prostate cell growth downstream of activated PI 3-kinase.

Authors: Frauke Leenders; Kristin Möpert; Anett Schmiedeknecht; Ansgar Santel; Frank Czauderna; Manuela Aleku; Silke Penschuck; Sibylle Dames; Maria Sternberger; Thomas Röhl; Axel Wellmann; Wolfgang Arnold; Klaus Giese; Jörg Kaufmann; Anke Klippel
Journal: EMBO J Date: 2004-07-29 Impact factor: 11.598

Protein kinase N3 deficiency impedes PI3-kinase pathway-driven leukemogenesis without affecting normal hematopoiesis.

Review 1. The multiple roles of PTEN in tumor suppression.

2. The interaction of PKN3 with RhoC promotes malignant growth.

3. Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at histone H3K4.

4. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia.

5. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor.

6. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia.

7. PKN3 is required for malignant prostate cell growth downstream of activated PI 3-kinase.

Review 8. The structure and function of PKN, a protein kinase having a catalytic domain homologous to that of PKC.

9. Regulatory domain selectivity in the cell-type specific PKN-dependence of cell migration.

10. Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell self-renewal and leukemia suppression.

1. Identification of 4-Anilinoquin(az)oline as a Cell-Active Protein Kinase Novel 3 (PKN3) Inhibitor Chemotype.

2. A Screen for PKN3 Substrates Reveals an Activating Phosphorylation of ARHGAP18.